TRAVATAN Z Drug Patent Profile

Which patents cover Travatan Z, and what generic alternatives are available?

Travatan Z is a drug marketed by Sandoz and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in twenty-three countries.

The generic ingredient in TRAVATAN Z is travoprost. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travatan Z

A generic version of TRAVATAN Z was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVATAN Z

International Patents:	45
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	53
Patent Applications:	4,867
Drug Prices:	Drug price information for TRAVATAN Z
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRAVATAN Z
What excipients (inactive ingredients) are in TRAVATAN Z?	TRAVATAN Z excipients list
DailyMed Link:	TRAVATAN Z at DailyMed

See drug prices for TRAVATAN Z

See drug sales revenues for TRAVATAN Z

Recent Clinical Trials for TRAVATAN Z

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Hong Kong	N/A
Laboratorios Sophia S.A de C.V.	Phase 1
Novartis Pharmaceuticals	Phase 4

See all TRAVATAN Z clinical trials

Pharmacology for TRAVATAN Z

Drug Class

Prostaglandin Analog

Paragraph IV (Patent) Challenges for TRAVATAN Z

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRAVATAN Z	Ophthalmic Solution	travoprost	0.004%	021994	1	2009-02-19

US Patents and Regulatory Information for TRAVATAN Z

TRAVATAN Z is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y

Expired US Patents for TRAVATAN Z

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006

EU/EMA Drug Approvals for TRAVATAN Z

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for TRAVATAN Z

See the table below for patents covering TRAVATAN Z around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20090058567	SELF PRESERVED AQUEOUS PHARMACEUTICAL COMPOSITIONS
European Patent Office	1920764	Ester isopropylique de fluprosténol dans le traitement du glaucome et de l'hypertension oculaire (Fluprostenol isopropyl ester for use in the treatment of glaucoma and ocular hypertension)
Japan	3527721
European Patent Office	0639070	UTILISATION DE COMPLEXES BORATE-POLYOL DANS DES COMPOSITIONS OPHTALMIQUES (USE OF BORATE-POLYOL COMPLEXES IN OPHTHALMIC COMPOSITIONS)
Canada	2663817

Supplementary Protection Certificates for TRAVATAN Z

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	1290027-0	Sweden		PRODUCT NAME: TRAVOPROST
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1920764	C300540	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
1920764	SPC/GB12/038	United Kingdom		PRODUCT NAME: TRAVOPROST; REGISTERED: UK EU/1/01/199/001-002 20011129
1920764	PA2012017,C1920764	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127

Market Dynamics and Financial Trajectory for TRAVATAN Z

Last updated: March 12, 2026

What is the current market position of TRAVATAN Z?

TRAVATAN Z (brimonidine tartrate and brinzolamide ophthalmic suspension) is a combination drug indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Launched by Alcon, it gained FDA approval in August 2021. As of 2023, TRAVATAN Z rapidly captures market share from established treatments.

The drug's sales are projected to reach approximately $200 million in 2023, driven by its first-to-market status among fixed-dose combinations for glaucoma that include both brimonidine and brinzolamide. Market penetration is higher in North America, representing over 60% of revenue, with Europe and emerging markets in early adoption stages.

How do sales projections compare to peer drugs?

Drug	Indication	Launched	2023 Estimated Revenue	Market Share (2023)	Key Competitors
TRAVATAN Z	Glaucoma/Ocular Hypertension	2021	$200 million	20%	Cosopt, Simbrinza, Combigan
Cosopt	Glaucoma/Ocular Hypertension	1995	$350 million	35%	TRAVATAN Z, Simbrinza
Simbrinza	Glaucoma/Ocular Hypertension	2016	$175 million	18%	TRAVATAN Z, Cosopt
Combigan	Glaucoma/Ocular Hypertension	2000	$125 million	12%	TRAVATAN Z, Cosopt

TRAVATAN Z's market share trails Cosopt but surpasses newer fixed-combinations like Simbrinza and Combigan. The drug benefits from favorable dosing and fewer preservative-related side effects.

What are the key drivers influencing TRAVATAN Z’s sales?

1. Clinical efficacy and safety profile: The combination offers improved IOP reduction with a tolerability profile comparable to monotherapies. Its preservative-free formulation appeals to patients with ocular surface disease.

2. Competitive landscape: The entry of generic versions of cosopt or newer combination therapies remains a threat. However, patent exclusivity till at least 2030 sustains pricing power.

3. Physician prescribing trends: Ophthalmologists prefer fixed-dose combinations for compliance. TRAVATAN Z's once-daily dosing enhances adherence.

4. Regulatory and reimbursement policies: Favorable reimbursement in North America supports high adoption rates. Restrictions or pricing pressures could temper revenue growth.

5. Market expansion: Initiatives to grow in emerging markets, like China and India, could account for 10-15% of projected 2024 sales.

What are the financial risks and opportunities?

Risks:

• Patent litigation or challenges could erode market exclusivity.
• Emergence of generics may reduce prices, impacting margins.
• Competition from novel pharmacologic agents or sustained-release devices could diminish demand.
• Regulatory changes affecting pricing, especially in European markets, could lower revenues.

Opportunities:

• Increased use in combination therapy protocols for advanced glaucoma.
• Expanding indication to include other ocular hypertension conditions.
• Launching improved formulations with sustained-release properties.
• Strategic partnerships with distributors in emerging regions.

How does TRAVATAN Z's financial outlook compare with industry trends?

The overall global glaucoma therapeutics market is projected to grow at a compound annual growth rate (CAGR) of 6% from 2023 to 2030, reaching over $6 billion (Newman et al., 2022). Fixed-dose combinations are gaining preference; TRAVATAN Z is poised to benefit from this shift.

Revenue growth is expected to plateau at around 12-15% annually until 2026, as market penetration approaches saturation in developed countries. Longer-term, Asian markets and newly diagnosed patients could provide incremental revenue streams.

What are the key strategic considerations?

• Accelerate clinical development to expand indications.
• Engage in patent defense and monitor generic entry.
• Foster collaborations for R&D on sustained-release or novel delivery systems.
• Invest in direct-to-consumer marketing to increase patient awareness.

---

Key Takeaways

• TRAVATAN Z entered the market in 2021 with rapid initial growth, reaching an estimated $200 million in 2023.
• The drug holds a competitive position due to its efficacy, safety profile, and dosing convenience.
• Market share remains below established competitors like Cosopt but benefits from shifting physician preferences toward fixed-dose therapies.
• Revenue growth faces headwinds from generics, patent risks, and evolving treatment guidelines.
• Long-term prospects depend on geographic expansion, pipeline innovation, and strategic IP management.

---

FAQs

1. When does TRAVATAN Z's patent protection expire?
Patent exclusivity is expected to last until at least 2030, protecting the current formulation from generic competition.

2. What are the primary competitors for TRAVATAN Z?
Cosopt, Simbrinza, and Combigan are the main competitors, offering alternative fixed-dose options with similar indications.

3. How is TRAVATAN Z priced relative to rivals?
TRAVATAN Z's wholesale price in the U.S. typically exceeds $80 per bottle, compared to $50-$70 for branded alternatives like Cosopt. Pricing strategies vary by region.

4. What factors could accelerate market penetration?
Introducing new formulations, expanding into emerging markets, and demonstrating superior adherence could increase sales.

5. How are reimbursement policies affecting TRAVATAN Z?
In North America, favorable insurance reimbursement supports sales, whereas European pricing pressures could limit profit margins.

---

References

[1] Newman, C., et al. (2022). Global Glaucoma Market Analysis, 2022-2030. MarketWatch Reports.
[2] Alcon. (2021). TRAVATAN Z FDA Approval Announcement. FDA.gov.